Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, and The Children’s Hospital of Philadelphia, Philadelphia, PA 19104-6021, USA.
Clin Infect Dis. 2013 Apr;56(8):1165-73. doi: 10.1093/cid/cit019. Epub 2013 Jan 29.
The burden of Cryptococcus neoformans in cerebrospinal fluid (CSF) predicts clinical outcomes in human immunodeficiency virus (HIV)-associated cryptococcal meningitis (CM) and is lower in patients on antiretroviral therapy (ART). This study tested the hypothesis that initiation of ART during initial treatment of HIV/CM would improve CSF clearance of C. neoformans.
A randomized treatment-strategy trial was conducted in Botswana. HIV-infected, ART-naive adults aged≥21 years initiating amphotericin B treatment for CM were randomized to ART initiation within 7 (intervention) vs after 28 days (control) of randomization, and the primary outcome of the rate of CSF clearance of C. neoformans over the subsequent 4 weeks was compared. Adverse events, including CM immune reconstitution inflammatory syndrome (CM-IRIS), and immunologic and virologic responses were compared over 24 weeks.
Among 27 subjects enrolled (13 intervention and 14 control), [corrected] the median times to ART initiation were 7 (interquartile range [IQR], 5–10) and 32days (IQR, 28–36), respectively. The estimated rate of CSF clearance did not differ significantly by treatment strategy (-0.32 log10 colony-forming units [CFU]/mL/day±0.20 intervention and -0.52 log10 CFUs/mL/day (±0.48) control, P=.4). Two of 13 (15%) and 5 of 14 (36%) subjects died in the intervention and control arms, respectively (P=0.39). Seven of 13 subjects (54%) in the intervention arm vs 0 of 14 in the control arm experienced CM-IRIS (P=.002).
Early ART was not associated with improved CSF fungal clearance, but resulted in a high risk of CM-IRIS. Further research on optimal incorporation of ART into CM care is needed.
NCT00976040.
新型隐球菌在脑脊液(CSF)中的负担可预测人类免疫缺陷病毒(HIV)相关隐球菌脑膜炎(CM)的临床结局,并且在接受抗逆转录病毒治疗(ART)的患者中较低。本研究检验了这样一个假设,即在 HIV/CM 的初始治疗中启动 ART 治疗可改善新型隐球菌在 CSF 中的清除率。
在博茨瓦纳进行了一项随机治疗策略试验。随机分配年龄≥21 岁、接受抗真菌药物两性霉素 B 治疗 CM 的 HIV 感染、ART 初治成年人,在随机分组后 7 天(干预组)或 28 天(对照组)开始 ART 治疗,比较随后 4 周内新型隐球菌 CSF 清除率的速率。比较 24 周内的不良事件,包括 CM 免疫重建炎症综合征(CM-IRIS)以及免疫和病毒学反应。
共纳入 27 名受试者(干预组 13 名,对照组 14 名),ART 开始的中位数时间分别为 7(四分位距[IQR],5-10)和 32 天(IQR,28-36)。治疗策略的 CSF 清除率估计值无显著差异(-0.32 log10 菌落形成单位[CFU]/mL/天±0.20 干预组和-0.52 log10 CFU/mL/天(±0.48)对照组,P=0.4)。干预组和对照组分别有 2 名(15%)和 5 名(36%)受试者死亡(P=0.39)。干预组 13 名受试者中有 7 名(54%)出现 CM-IRIS,而对照组 14 名受试者中无 1 名(0%)出现 CM-IRIS(P=0.002)。
早期 ART 治疗与改善 CSF 真菌清除率无关,但会导致 CM-IRIS 的高风险。需要进一步研究将 ART 纳入 CM 护理的最佳方法。
NCT00976040。